Australia markets closed

  • ALL ORDS

    7,082.20
    -58.80 (-0.82%)
     

  • AUD/USD

    0.6326
    +0.0020 (+0.31%)
     

  • ASX 200

    6,890.20
    -53.20 (-0.77%)
     

  • OIL

    88.11
    -1.12 (-1.26%)
     

  • GOLD

    1,837.60
    -3.90 (-0.21%)
     

  • Bitcoin AUD

    43,591.34
    +4.10 (+0.01%)
     

  • CMC Crypto 200

    587.57
    -2.40 (-0.41%)
     
FEELING THE PINCH? :

Beat the cost-of-living squeeze with our pro tips and helpful hacks - sign up now

Establishment Labs to Present at the Cowen 43rd Annual Health Care Conference

Business Wire
·2-min read

NEW YORK, February 28, 2023--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced that Juan José Chacón-Quirós, Founder and Chief Executive Officer, and Raj Denhoy, Chief Financial Officer, will present at the Cowen 43rd Annual Health Care Conference on Tuesday, March 7, 2023, at 9:50 am Eastern Time.

A live webcast of the presentation will be available on the Establishment Labs investor relations website at https://investors.establishmentlabs.com/. An archived version of the webcast will be available on the same website following the completion of the event.

About Establishment Labs

Establishment Labs Holdings Inc. is a global medical technology company dedicated to improving women’s health and wellness. The company’s initial focus is breast health, principally breast aesthetics and reconstruction. Establishment Labs offers a portfolio of advanced silicone gel-filled breast implants, branded as Motiva®, that include a number of innovative and patented features designed to deliver improved aesthetic and clinical outcomes. Since commercial launch in 2010, over 2.5 million Motiva Implants® have been delivered to plastic surgeons in over 80 countries. The company also offers or has under development a number of related products and technologies, including the Motiva Flora® tissue expander and Mia Femtech™, the company’s minimally invasive breast enhancement procedure. In 2018, Establishment Labs received an investigational device exemption (IDE) from the FDA for the Motiva Implant® and began a clinical trial to support regulatory approval in the United States. Motiva Implants® are manufactured at the company’s two facilities in Costa Rica, which are compliant with all applicable regulatory standards under ISO13485:2016 and FDA 21 CFR 820 under the MDSAP program. Please visit our website for additional information at www.establishmentlabs.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005119/en/

Contacts

Investor/Media Contact:
Raj Denhoy
415-828-1044
rdenhoy@establishmentlabs.com